Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population

Clinica Chimica Acta

Volumn 416, Issue , 2013, Pages 11-19

  Islam, Mohammad Safiqul ^a   Ahmed, Maizbha Uddin ^a   Bin Sayeed, Muhammad Shahdaat ^a   Al Maruf, Abdullah ^a   Mostofa, A G M ^a   Akram Hussain, Syed Md ^b   Kabir, Yearul ^a   Daly, Ann K ^c   Hasnat, Abul ^a  

^a UNIVERSITY OF DHAKA   (Bangladesh)

^b BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bangladeshi population; CHRNA5; CYP1A1; CYP2A6; Lung cancer; Smokers

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2A6; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA5; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; AGE; ALLELE; ARTICLE; BANGLADESH; BANGLADESHI; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHRNA5 GENE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYP1A1 GENE; CYP2A6 GENE; ETHNIC GROUP; FEMALE; GENE DELETION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; LARGE CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING;

ARYL HYDROCARBON HYDROXYLASES; BANGLADESH; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LUNG NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, NICOTINIC; RISK FACTORS; SMOKING;

NICOTIANA TABACUM;

EID: 84870976154     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.11.011     Document Type: Article

References (66)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer, Lyon, France, [Available from: http://globocan.iarc.fr; last accessed: July 1, 2012].
3. Haque A.F.M.R. Prevention and control of noncommunicable diseases: the Bangladesh perspective. Commonwealth Health Ministers' Update 2011 2011, 100-101. Pro-Brook Publishing Limited, Melton, Woodbridge, Suffolk.
4. World Health Organization (WHO) Impact of tobacco-related illnesses in Bangladesh 2007, WHO Regional Office for South-East Asia, New Delhi, India, [www.searo.who.int/linkfiles/tobacco_free_initiative_health_cost_bangladesh.pdf; last accessed: July 1, 2012].
5. Tang L., Zirpoli G.R., Jayaprakash V., et al. Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers: a case-control study. BMC Cancer 2010, 10:162.
6. Zagà V., Lygidakis C., Chaouachi K., Gattavecchia E. Polonium and lung cancer. J Oncol 2011, 2011:860103.
7. U.S.Department of Health and Human Services How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. A report of the surgeon general 2010, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
8. Rahman M.H., Arslan M.I., Chen Y., et al. Polycyclic aromatic hydrocarbon-DNA adducts among rickshaw drivers in Dhaka City, Bangladesh. Int Arch Occup Environ Health 2003, 76(7):533-538.
9. Bartsch H., Petruzzelli S., De Flora S., et al. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 1992, 98:119-124.
10. [1 July, 2012, date last accessed]. http://www.cypalleles.ki.se.
11. Zhan P., Wang Q., Qian Q., Wei S.Z., Yu L.K. CYP1A1 MspI and exon 7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. J Exp Clin Cancer Res 2011, 30:99.
12. Chen Z., Li Z., Niu X., et al. The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis 2011, 26(3):437-446.
13. Persson I., Johansson I., Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997, 231(1):227-230.
14. Wang J.J., Zheng Y., Sun L., et al. CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies. Eur J Cancer Prev 2011, 20(6):445-452.
15. Wright C.M., Larsen J.E., Colosimo M.L., et al. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur Respir J 2010, 35(1):152-159.
16. Cascorbi I., Brockmoller J., Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996, 56(21):4965-4969.
17. Schwarz D., Kisselev P., Cascorbi I., Schunck W.H., Roots I. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 2001, 22(3):453-459.
18. Singh V., Rastogi N., Sinha A., Kumar A., Mathur N., Singh M.P. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Breast Cancer Res Treat 2007, 101(1):73-81.
19. Shah P.P., Singh A.P., Singh M., et al. Interaction of cytochrome P4501A1 genotypes with other risk factors and susceptibility to lung cancer. Mutat Res 2008, 639(1-2):1-10.
20. Kiyohara C., Nakanishi Y., Inutsuka S., et al. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 1998, 8(4):315-323.
21. Zhang Z.Y., Fasco M.J., Huang L., Guengerich F.P., Kaminsky L.S. Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996, 56(17):3926-3933.
22. Di Y.M., Chow V.D., Yang L.P., Zhou S.F. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009, 10(7):754-780.
23. Rao Y., Hoffmann E., Zia M., et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000, 58(4):747-755.
24. Mwenifumbo J.C., Zhou Q., Benowitz N.L., Sellers E.M., Tyndale R.F. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics 2010, 11(2):189-198.
25. Oscarson M., McLellan R.A., Gullstén H., et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999, 448:105-110.
26. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J.T., Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003, 74(1):69-76.
27. Mwenifumbo J.C., Myers M.G., Wall T.L., Lin S.K., Sellers E.M., Tyndale R.F. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 2005, 15:189-192.
28. Mwenifumbo J.C., Lessov-Schlaggar C.N., Zhou Q., et al. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 2008, 83:115-121.
29. Liu T., David S.P., Tyndale R.F., et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 2011, 106(5):985-994.
30. Soriano A., Vicente J., Carcas C., et al. Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. Fundam Clin Pharmacol 2011, 25(5):627-632.
31. Hung R.J., McKay J.D., Gaborieau V., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
32. Thorgeirsson T.E., Geller F., Sulem P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452(7187):638-642.
33. Amos C.I., Wu X., Broderick P., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008, 40(5):616-622.
34. Truong T., Hung R.J., Amos C.I., et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst 2010, 102(13):959-971.
35. Tournier J.M., Birembaut P. Nicotinic acetylcholine receptors and predisposition to lung cancer. Curr Opin Oncol 2011, 23(1):83-87.
36. The International HapMap Project [1 July, 2012, date last accessed]. http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap27_B36/?name=SNP%3Ars16969968.
37. Reich D., Thangaraj K., Patterson N., Price A.L., Singh L. Reconstructing Indian population history. Nature 2009, 461(7263):489-494.
38. Mehra N.K. Defining genetic architecture of the populations in the Indian subcontinent: impact of human leukocyte antigen diversity studies. Indian J Hum Genet 2010, 16(3):105-107.
39. Travis W.D. Pathology of lung cancer. Clin Chest Med 2011, 32(4):669-692.
40. World Medical Association Declaration of Helsinki Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 59th WMA General Assembly Seoul, South Korea, October, 2008 2008, [http://www.wma.net/en/30publications/10policies/b3/index.html (1 July, 2012, date last accessed).].
41. Daly A.K., Monkman S.C., Smart J., Steward A., Cholerton S. Analysis of cytochrome P450 polymorphisms. Methods Mol Biol 1998, 107:405-422.
42. Hayashi S., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 1991, 110(3):407-411.
43. Daly A.K., King B.P., Leathart J.B. Genotyping for cytochrome P450 polymorphisms. Methods Mol Biol 2006, 320:193-207.
44. Nakajima M., Kwon J.T., Tanaka N., et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001, 69(1):72-78.
45. Bierut L.J., Stitzel J.A., Wang J.C., et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008, 165(9):1163-1171.
46. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
47. Smart J., Daly A.K. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000, 10(1):11-24.
48. San Jose C., Cabanillas A., Benitez J., Carrillo J.A., Jimenez M., Gervasini G. CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study. BMC Cancer 2010, 10:463.
49. Song N., Tan W., Xing D., Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 2001, 22(1):11-16.
50. Tamaki Y., Arai T., Sugimura H., et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet 2011, 26(5):516-522.
51. Ihsan R., Chauhan P.S., Mishra A.K., et al. Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One 2011, 6(12):e29431.
52. Shaffi S.M., Shah M.A., Bhat I.A., Koul P., Ahmad S.N., Siddiqi M.A. CYP1A1 polymorphisms and risk of lung cancer in the ethnic Kashmiri population. Asian Pac J Cancer Prev 2009, 10:651-656.
53. Fujieda M., Yamazaki H., Saito T., et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004, 25(12):2451-2458.
54. Hirvonen A., Husgafvel-Pursiainen K., Karjalainen A., Anttila S., Vainio H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992, 1:485-489.
55. Vineis P., Veglia F., Benhamou S., et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 2003, 104:650-657.
56. Tan W., Chen G.F., Xing D.Y., Song C.Y., Kadlubar F.F., Lin D.X. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 2001, 95(2):96-101.
57. Loriot M.A., Rebuissou S., Oscarson M., et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001, 11(1):39-44.
58. Krishnakumar D., Gurusamy U., Dhandapani K., et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol 2012, 26(2):295-306.
59. Saccone S.F., Hinrichs A.L., Saccone N.L., et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007, 16(1):36-49.
60. Stevens V.L., Bierut L.J., Talbot J.T., et al. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3517-3525.
61. Ito H., McKay J.D., Hosono S., et al. Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. J Thorac Oncol 2012, 7(5):790-798.
62. Shiraishi K., Kohno T., Kunitoh H., et al. Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis 2009, 30(1):65-70.
63. Timofeeva M.N., McKay J.D., Smith G.D., et al. Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol Biomarkers Prev 2011, 20(10):2250-2261.
64. Lips E.H., Gaborieau V., McKay J.D., et al. Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol 2010, 39(2):563-577.
65. Wu C., Hu Z., Yu D., et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. Cancer Res 2009, 69(12):5065-5072.
66. International Agency for Research on Cancer Tobacco smoking. IARC monographs on the evaluation of carcinogenic risks to humans 1986, vol. 38:1-3. IARC, Lyon (France).